Original reporting and analysis on the stories shaping biotech.
The FDA just approved a CRISPR gene therapy for kids as young as two, a world first. Casgevy's expansion into toddlers could prevent the silent organ damage that sickle cell disease inflicts from infancy, but delivering a treatment this complex to tiny patients is a whole different challenge.
Pfizer's sigvotatug vedotin, a key ADC from its $43 billion Seagen acquisition, just failed its pivotal lung cancer trial. The Seagen bet isn't dead yet, but the margin for error is shrinking fast.
AbbVie is paying $10.9 billion for a company that was founded in 2022 and has zero approved drugs. The bet: a next-gen eczema and asthma antibody that could challenge Dupixent with shots every three to six months instead of every two weeks.
The NIH just joined a $5 billion, 15-agency federal AI initiative that aims to cut drug development timelines in half. It's the biggest bet on AI-driven biomedical research in U.S. history, and it comes with some serious strings attached.
The House just passed a bill forcing the FDA to stop defaulting to animal testing in its drug approval rules. With animal studies costing up to $1.1 billion per approved drug and adding years to development timelines, the biotech industry's preclinical playbook is about to get a serious rewrite.
A tiny startup just raised $62 million to repurpose cancer's most powerful cell-killing technology against autoimmune disease. The monkey data look stunning, but the real test is just getting started.
An international team just published AI-designed proteins that sit dormant until they detect a specific molecular target, then snap to life like programmable switches. The implications for diagnostics, drug delivery, and precision medicine are enormous, and the framework is what really changes the game.
The FDA just fast-tracked Pfizer's PARP inhibitor combo for an earlier stage of prostate cancer where no targeted therapy exists. If approved, it could reshape how tens of thousands of men are treated at first diagnosis and give Pfizer a crucial first-mover advantage in a wide-open market.
Eli Lilly is now selling the highest doses of Zepbound in single-dose vials for $449 per month, roughly 60% cheaper than the standard auto-injector pens. It's a strategic play in a GLP-1 pricing war that's reshaping who can actually afford obesity drugs.
Roche killed its lupus T-cell engager after early data fell short, but immediately doubled down on autoimmune cell therapies through its $1.5 billion Poseida deal. The move reveals a critical tension in the hottest space in biotech: cancer-grade immune weapons might be too blunt for autoimmune disease.
The Senate unanimously passed a bill capping the patents a biologic maker can assert against biosimilar challengers at 20. With blockbusters like Keytruda and Dupixent protected by 80 to 130+ patents each, the legislation could reshape how pharma defends its biggest drugs.
The FDA just approved a fifth targeted drug for ROS1-positive lung cancer, a rare mutation that hits only 1-2% of patients. Jideytro is built to work when the other four drugs have already failed, and its brain-penetration data might be the most impressive part.
A Swiss startup just tested a battery-less brain implant that beams neural data through your skin using infrared light. If the tech holds up in chronic trials, it could reshape the entire brain-computer interface field.
Repligen is spending $1.5 billion to acquire BioLife Solutions, the company whose biopreservation media keeps living cells alive in roughly 90% of approved cell therapies. It's the biggest picks-and-shovels play in cell therapy manufacturing this year, and it says a lot about where the real money is flowing.
The FDA wants to hire 2,200 people after losing over 3,000 in last year's cuts, while simultaneously overhauling how clinical trials are evaluated. Executives are cautiously hopeful, but the math on staffing doesn't add up yet, and the trust deficit may be harder to fix than the headcount.
Novo Nordisk filed a federal lawsuit accusing Eli Lilly of running deceptive ads that make Zepbound and Mounjaro look superior by cherry-picking dose comparisons. In a market racing toward $100 billion, the fight over who gets to say "we're better" just landed in court.
Allogene's ALLO-316 just did what no off-the-shelf CAR-T therapy has done before: produce durable remissions in metastatic solid tumors. The Phase 1 data, published in the Journal of Clinical Oncology, could redraw the boundaries of cell therapy.
Crystalys just raised $130M to bring a gout drug already approved in five Asian countries to the U.S. With a competing therapy just rejected by the FDA and millions of American patients stuck with limited options, the timing couldn't be better.
ARPA-H just dropped $160 million on seven teams racing to make gene therapy work like a software platform: swap one piece of code, treat a whole new disease. If the aggressive timelines and novel regulatory models pan out, it could reshape how we think about curing the rarest genetic conditions.
J&J's OTTAVA just became the first table-integrated surgical robot to earn FDA authorization, creating an entirely new device category. After a decade of delays, billion-dollar lawsuits, and a $900 million write-down, the fight for Intuitive Surgical's robotic surgery throne just got real.
Leqembi just became the first Alzheimer's drug you can take entirely at home, from first dose to last. With nine-month clinic waitlists and infusion-center bottlenecks choking patient access, this FDA approval could reshape who actually gets treated.
GSK's partner Hansoh just delivered the first-ever Phase 3 survival win for a B7-H3 antibody-drug conjugate in small-cell lung cancer. In one of oncology's most competitive target races, being first to prove patients live longer is a powerful opening move.
Join thousands of biotech professionals who start their day with our free, daily briefing.